Evaluation of Early and Mid-term Results of TEVAR Procedures with Various Etiology
No Thumbnail Available
Date
2019
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Endovascular aneurysm repair in thoracic aorta (TEVAR) is now preferred primarily for the treatment of degenerative aneurysms, saccular aneurysms and acute thoracic aortic syndromes. The aim of this study was to evaluate the early and mid-term results of TEVAR procedures that performed in our clinic in the last 3 years. Materials and Method: Thirty patients (25 males, 5 females) underwent TEVAR procedure between January 2015 and December 2018. Valiant ™ Thoracic Stent Graft System (Medtronic®) was used in all patients. Results: The mean age of the patients was 60.4±18. Of the patients, 53.3% had degenerative aneurysm origin, 36.7% had acute thoracic aortic syndromes and 10% had aortic coarctation and concomitant post-stenotic aneurysm. 63.3% of the patients were symptomatic and had back or chest pain. Technical success of the procedures was 100%. The mean duration of stay in the intensive care unit was 1 ± 2 days and the mean hospital stay was 3.2 ± 2 days. There was no in-hospital mortality and one patient died of type 2 dissection in the first 30-day period. Two, type II endoleak was seen in two patients and we did not need a secondary intervention as the endoleaks resolved spontaneously. The subclavian artery was required to be closed in 3 patients. We did not observed stroke in those patients and no ischemia developed in the left upper extremity. Despite adequate hydration, in the early postoperative period, 2 patients had elevated creatinine levels and regressed to the normal values in the follow-up. The mean follow-up period was 6 ± 9 months and there were 2 mortality in the long term. One patient died of lungcancer and the second died of mesenteric ischemia independently from aneurysmal disease.Conclusion: TEVAR is the first line therapeutic option in anatomically suitable patients for the treatment ofaneurysmal disease of thoracic aorta or acute thoracic aortic syndromes. TEVAR can be applied safely with lowmorbidity and mortality. Nowadays, as sporting amateur or professional participation increases, the importance ofsportive performance and the factors affecting this performance increase. The genetic background in sports has agreat impact on the strength, endurance, muscle mass, muscle fibers and lung capacity. Sports genetics studiesinclude the whole range of studies in determining the genes affecting athletic performance, clarifying themechanisms of action and determining their susceptibility to athletic performance. Examples of genes that can beassociated with athletic performance include; can list genes such as myostatin, erythropoietin, growth hormone,nitric oxide synthase, vascular endothelial growth factor, angiotensin converting enzyme, angiotensinogen,monocarboxylate carrier 1, insulin-like growth factor-1, peroxisome proliferator active receptor, alpha-actinin-3.The aim of this study is to investigate genes that are effective in sports science and sports performance.